6UCS image
Entry Detail
PDB ID:
6UCS
Keywords:
Title:
Discovery and Structure-Based optimization of potent and selective WDR5 inhibitors containing a dihydroisoquinolinone bicyclic core
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2019-09-17
Release Date:
2020-01-01
Method Details:
Experimental Method:
Resolution:
1.85 Å
R-Value Free:
0.19
R-Value Work:
0.16
R-Value Observed:
0.16
Space Group:
P 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:WD repeat-containing protein 5
Chain IDs:A, B
Chain Length:313
Number of Molecules:2
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core.
J.Med.Chem. 63 656 675 (2020)
PMID: 31858797 DOI: 10.1021/acs.jmedchem.9b01608

Abstact

WD repeat domain 5 (WDR5) is a member of the WD40-repeat protein family that plays a critical role in multiple chromatin-centric processes. Overexpression of WDR5 correlates with a poor clinical outcome in many human cancers, and WDR5 itself has emerged as an attractive target for therapy. Most drug-discovery efforts center on the WIN site of WDR5 that is responsible for the recruitment of WDR5 to chromatin. Here, we describe discovery of a novel WDR5 WIN site antagonists containing a dihydroisoquinolinone bicyclic core using a structure-based design. These compounds exhibit picomolar binding affinity and selective concentration-dependent antiproliferative activities in sensitive MLL-fusion cell lines. Furthermore, these WDR5 WIN site binders inhibit proliferation in MYC-driven cancer cells and reduce MYC recruitment to chromatin at MYC/WDR5 co-bound genes. Thus, these molecules are useful probes to study the implication of WDR5 inhibition in cancers and serve as a potential starting point toward the discovery of anti-WDR5 therapeutics.

Legend

Protein

Chemical

Disease

Primary Citation of related structures